# Doctors can't test for new drugs fast enough

> Rapid tests for emerging synthetic drugs exist, but FDA rules keep them out of hospitals when patients need them most.
- Title: Doctors can't test for new drugs fast enough · TIME | Shortify
- Summary: Rapid tests for emerging synthetic drugs exist, but FDA rules keep them out of hospitals when patients need them most. FDA regulations prevent hospitals from…
- Keywords: drug testing, fda regulation, overdose crisis, synthetic drugs, emergency medicine, healthcare policy, news, world, Doctors, can't, test, drugs
- Source: TIME — https://time.com/article/2026/11/01/why-doctors-are-last-to-know-what-s-in-the-drug-supply
- Author: Dr. Shravani Durbhakula
- Published: 2026-11-01T11:00:03.151+00:00
- Read time: 1 min
- Topics: drug testing, fda regulation, overdose crisis, synthetic drugs, emergency medicine, healthcare policy, news, world
## New drugs spread faster than tests
Nitazenes, medetomidine, cychlorphine and other novel synthetic substances are appearing in rapid succession in the illicit drug supply. Rapid tests for these drugs exist and return results within minutes.
## Tests work everywhere except hospitals
Law enforcement, medical examiners, employers, community organizations and the general public can use rapid drug tests. Physicians treating overdoses in emergency rooms cannot, even when minutes are essential.

> A test can be used to fire someone or support a criminal case, yet it remains unavailable to the physician in an emergency room trying to save that person's life, when minutes are essential.
## FDA rules create the divide
Many tests for emerging drugs are labeled for forensic use only. Clinical tests for living patients require FDA approval as a diagnostic tool and cannot legally be used by medical clinics that follow federal law.
## Xylazine and medetomidine changed treatment
Starting in 2020, xylazine spread through the fentanyl supply. It does not respond to naloxone and causes necrotic skin wounds increasing sepsis risk. Medetomidine later overtook xylazine supplies with similar dangers.
## Doctors work blind without bedside tests
There are no point-of-care tests for xylazine, medetomidine or cychlorphine. Clinicians follow information from law-enforcement seizures, public-health alerts and months-old fatality data rather than tests at the bedside.
## FDA should fast-track emerging drug tests
The FDA should establish an expedited pathway for clinical tests when the CDC or Office of National Drug Control Policy identifies a substance of significant public-health concern. Federal agencies could fund independent validation.
## Better data saves lives and warns early
Rapid drug screens at the bedside would help physicians make better treatment decisions. Better hospital data could become an early-warning system rather than a retrospective record of a crisis already underway.

> Emergency departments are on the front lines of the overdose crisis; they should have access to the most innovative testing tools at the bedside, when minutes can make a difference.
## Key takeaway

FDA regulations prevent hospitals from using rapid drug tests available to law enforcement, leaving doctors treating overdoses without real-time information on what patients have taken.